|
US3512676A
(en)
*
|
1967-08-07 |
1970-05-19 |
Wsr Inc |
Container end structure
|
|
US6355476B1
(en)
|
1988-11-07 |
2002-03-12 |
Advanced Research And Technologyinc |
Nucleic acid encoding MIP-1α Lymphokine
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
US6362325B1
(en)
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
|
US5149797A
(en)
|
1990-02-15 |
1992-09-22 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of rna and production of encoded polypeptides
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US5652355A
(en)
|
1992-07-23 |
1997-07-29 |
Worcester Foundation For Experimental Biology |
Hybrid oligonucleotide phosphorothioates
|
|
US6346614B1
(en)
|
1992-07-23 |
2002-02-12 |
Hybridon, Inc. |
Hybrid oligonucleotide phosphorothioates
|
|
TW244371B
(https=)
|
1992-07-23 |
1995-04-01 |
Tri Clover Inc |
|
|
US6084067A
(en)
|
1993-07-26 |
2000-07-04 |
Dana-Farber Cancer Institute |
CTLA4/CD28 ligands and uses therefor
|
|
US5855887A
(en)
|
1995-07-25 |
1999-01-05 |
The Regents Of The University Of California |
Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US5912332A
(en)
|
1996-07-26 |
1999-06-15 |
Hybridon, Inc. |
Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
|
|
US6113881A
(en)
|
1996-09-20 |
2000-09-05 |
Helene Curtis, Inc. |
Hair styling mousse compositions comprising carboxylated polyurethane resins
|
|
RU2192281C2
(ru)
|
1996-10-11 |
2002-11-10 |
Бристол-Маерс Сквибб Компани |
Способы и композиции для иммуномодуляции
|
|
JP2001523958A
(ja)
|
1997-03-21 |
2001-11-27 |
ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド |
免疫療法のｃｔｌａ−４結合ペプチド
|
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
|
DK1141028T3
(da)
|
1998-12-23 |
2010-05-25 |
Pfizer |
Humane monoklonale antistoffer til CTLA-4
|
|
FR2795937B1
(fr)
|
1999-07-09 |
2001-09-14 |
Air Liquide |
Machine de croutage en ligne
|
|
EP1210428B1
(en)
|
1999-08-23 |
2015-03-18 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
|
IL148079A0
(en)
|
1999-08-24 |
2002-09-12 |
Medarex Inc |
Human ctla-4 antibodies and compositions containing the same
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
US20040214783A1
(en)
*
|
2002-05-08 |
2004-10-28 |
Terman David S. |
Compositions and methods for treatment of neoplastic disease
|
|
DE19941311C1
(de)
|
1999-08-31 |
2001-06-07 |
Cryoelectra Ges Fuer Kryoelek |
Bandfilter
|
|
CA2386270A1
(en)
|
1999-10-15 |
2001-04-26 |
University Of Massachusetts |
Rna interference pathway genes as tools for targeted genetic interference
|
|
EP1261376A1
(en)
|
2000-01-27 |
2002-12-04 |
Genetics Institute, LLC |
Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
|
|
PT1309726E
(pt)
|
2000-03-30 |
2010-03-08 |
Whitehead Biomedical Inst |
Mediadores de interferência por rna específicos de sequência de rna
|
|
US20040259247A1
(en)
|
2000-12-01 |
2004-12-23 |
Thomas Tuschl |
Rna interference mediating small rna molecules
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
WO2003011911A1
(fr)
|
2001-07-31 |
2003-02-13 |
Ono Pharmaceutical Co., Ltd. |
Substance specifique pour pd-1
|
|
BR0309254A
(pt)
|
2002-04-12 |
2005-03-01 |
Medarex Inc |
Uso de um anticorpo anti-ctla-4
|
|
ES2350687T3
(es)
|
2002-07-03 |
2011-01-26 |
Ono Pharmaceutical Co., Ltd. |
Composiciones de inmunopotenciación.
|
|
PL375144A1
(en)
|
2002-07-30 |
2005-11-28 |
Bristol-Myers Squibb Company |
Humanized antibodies against human 4-1bb
|
|
CN101928344B
(zh)
|
2002-10-17 |
2014-08-13 |
根马布股份公司 |
抗cd20的人单克隆抗体
|
|
US8039443B2
(en)
|
2002-11-21 |
2011-10-18 |
Archemix Corporation |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
CN1753912B
(zh)
|
2002-12-23 |
2011-11-02 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US7563869B2
(en)
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
|
FI1897548T4
(fi)
|
2003-02-28 |
2024-09-03 |
The Johns Hopkins University |
T-solujen säätely
|
|
WO2004081021A2
(en)
|
2003-03-12 |
2004-09-23 |
Duke University |
Oligonucleotide mimetics
|
|
US20050250106A1
(en)
|
2003-04-24 |
2005-11-10 |
David Epstein |
Gene knock-down by intracellular expression of aptamers
|
|
MXPA06000619A
(es)
*
|
2003-07-15 |
2006-04-11 |
Hybridon Inc |
Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
|
|
CN100482673C
(zh)
*
|
2003-07-15 |
2009-04-29 |
艾德拉药物股份有限公司 |
使用免疫刺激性寡核苷酸和/或免疫子化合物结合细胞因子和/或化疗剂或放射治疗对免疫系统的协同刺激作用
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
EP1732600A2
(en)
|
2004-03-26 |
2006-12-20 |
Pfizer Products Incorporated |
Uses of anti-ctla-4 antibodies
|
|
US20060014713A1
(en)
*
|
2004-06-15 |
2006-01-19 |
Hybridon, Inc. |
Immunostimulatory oligonucleotide multimers
|
|
CA2570812C
(en)
|
2004-06-18 |
2014-07-29 |
The Regents Of The University Of California |
Brassica indehiscent1 sequences
|
|
US8239749B2
(en)
|
2004-06-25 |
2012-08-07 |
Apple Inc. |
Procedurally expressing graphic objects for web pages
|
|
US20090252741A1
(en)
|
2004-09-08 |
2009-10-08 |
Ohio State University Research Foundation |
Human monoclonal anti-ctla4 antibodies in cancer treatment
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
CN101355965A
(zh)
|
2005-06-08 |
2009-01-28 |
达纳－法伯癌症研究院 |
通过抑制程序性细胞死亡1（pd-1）途经治疗持续性感染和癌症的方法及组合物
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
JP2009500412A
(ja)
*
|
2005-07-07 |
2009-01-08 |
コーリー ファーマシューティカル グループ，インコーポレイテッド |
癌の処置のための、抗ｃｔｌａ−４抗体とｃｐｇモチーフ含有合成オリゴデオキシヌクレオチドとの組み合わせ治療
|
|
CA2626547A1
(en)
*
|
2005-10-21 |
2007-05-03 |
Medical College Of Georgia Research Institute, Inc. |
The induction of indoleamine 2,3-dioxygenase in dendritic cells by tlr ligands and uses thereof
|
|
NZ568211A
(en)
*
|
2005-11-04 |
2011-11-25 |
Novartis Vaccines & Diagnostic |
Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
|
|
US7786089B2
(en)
*
|
2005-12-20 |
2010-08-31 |
Idera Pharmaceuticals, Inc. |
Immunostimulatory activity of immune modulatory oligonucleotides (IMO™) containing different lengths of palindromic segments
|
|
JP6092497B2
(ja)
|
2006-03-30 |
2017-03-08 |
ユニバーシティー オブ カリフォルニア |
抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
|
|
US20080031887A1
(en)
*
|
2006-06-30 |
2008-02-07 |
Joseph Lustgarten |
Conjugates for inducing targeted immune responses and methods of making and using same
|
|
CN101104640A
(zh)
|
2006-07-10 |
2008-01-16 |
苏州大学 |
抗人pd-l1单克隆抗体制备及应用
|
|
JP2008066402A
(ja)
|
2006-09-05 |
2008-03-21 |
Fujifilm Corp |
撮像素子および撮像装置
|
|
MX2009006230A
(es)
|
2006-12-12 |
2009-06-22 |
Idera Pharmaceuticals Inc |
Agonistas sinteticos de receptores de tipo toll 9.
|
|
WO2008100562A2
(en)
*
|
2007-02-14 |
2008-08-21 |
Medical College Of Georgia Research Institute, Inc. |
Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
HRP20131167T1
(hr)
|
2007-06-18 |
2014-01-03 |
Merck Sharp & Dohme B.V. |
Antitijela za humani receptor programirane smrti pd-1
|
|
KR20090010580A
(ko)
|
2007-07-24 |
2009-01-30 |
조용식 |
페트용 토이렛
|
|
KR20100053598A
(ko)
|
2007-08-01 |
2010-05-20 |
이데라 파마슈티칼즈, 인코포레이티드 |
Ｔｌｒ９의 신규한 합성 효능제
|
|
EP2212350B1
(en)
|
2007-10-26 |
2013-08-28 |
Governing Council of the University of Toronto |
Treating chronic viral infection by targetting TIM-3
|
|
US20120129870A1
(en)
|
2007-12-17 |
2012-05-24 |
Wenying Chai |
Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor
|
|
WO2009100140A1
(en)
|
2008-02-04 |
2009-08-13 |
Medarex, Inc. |
Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
|
|
GB2457346B
(en)
|
2008-02-12 |
2012-03-28 |
Scott Cutters Uk Ltd |
Cutting tools
|
|
US8460886B2
(en)
|
2008-07-04 |
2013-06-11 |
Ono Pharmaceutical Co., Ltd. |
Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human PD-1 antibody on cancers
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
JP5794917B2
(ja)
|
2008-09-12 |
2015-10-14 |
アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ |
Ｐｄ−１特異抗体およびその使用
|
|
KR101814408B1
(ko)
|
2008-09-26 |
2018-01-04 |
다나-파버 캔서 인스티튜트 인크. |
인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
|
|
AU2009333580B2
(en)
|
2008-12-09 |
2016-07-07 |
Genentech, Inc. |
Anti-PD-L1 antibodies and their use to enhance T-cell function
|
|
WO2010089411A2
(en)
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
US8605955B2
(en)
|
2009-06-29 |
2013-12-10 |
DigitalOptics Corporation Europe Limited |
Methods and apparatuses for half-face detection
|
|
JP5409275B2
(ja)
|
2009-11-06 |
2014-02-05 |
アズビル株式会社 |
監視制御システム
|
|
EP2533779A4
(en)
*
|
2010-02-09 |
2013-08-21 |
Georgia Health Sciences University Res Inst Inc |
ALPHA-METHYL-TRYPTOPHANE AS INHIBITORS OF INDOLEAMINE DIOXYGENASE
|
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
CN102892786B
(zh)
|
2010-03-11 |
2016-03-16 |
Ucb医药有限公司 |
Pd-1抗体
|
|
CA2792561C
(en)
|
2010-04-06 |
2021-10-26 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of cd274/pd-l1 gene
|
|
BR112012029066A2
(pt)
*
|
2010-05-14 |
2020-09-01 |
The General Hospital Corporation |
composições e processos de identificação de neoantígenos específicos de tumor.
|
|
JP2013532153A
(ja)
|
2010-06-18 |
2013-08-15 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
|
|
FR2963448A1
(fr)
|
2010-07-29 |
2012-02-03 |
Sagem Defense Securite |
Procede et systeme d'analyse de donnees de vol enregistrees au cours d'un vol d'un avion.
|
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
|
KR101970025B1
(ko)
|
2011-04-20 |
2019-04-17 |
메디뮨 엘엘씨 |
Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
|
|
US8841418B2
(en)
|
2011-07-01 |
2014-09-23 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to TIM3
|
|
US20130018499A1
(en)
|
2011-07-12 |
2013-01-17 |
The Boeing Company |
Producibility analysis during engineering design of composite parts
|
|
JP6238459B2
(ja)
|
2011-08-01 |
2017-11-29 |
ジェネンテック， インコーポレイテッド |
Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
|
|
EP2742953B1
(en)
|
2011-08-11 |
2021-09-22 |
ONO Pharmaceutical Co., Ltd. |
Therapeutic agent for autoimmune diseases comprising pd-1 agonist
|
|
HUE059406T2
(hu)
|
2011-10-17 |
2022-11-28 |
Io Biotech Aps |
PD-L1 alapú immunterápia
|
|
HRP20201595T1
(hr)
|
2011-11-28 |
2020-12-11 |
Merck Patent Gmbh |
Anti-pd-l1 protutijela i njihova uporaba
|
|
WO2013132317A1
(en)
|
2012-03-07 |
2013-09-12 |
Aurigene Discovery Technologies Limited |
Peptidomimetic compounds as immunomodulators
|
|
HK1204557A1
(en)
|
2012-05-31 |
2015-11-27 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-l1
|
|
JP6457940B2
(ja)
|
2012-08-30 |
2019-01-23 |
アムジエン・インコーポレーテツド |
単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法
|
|
CN105163754B
(zh)
*
|
2012-09-20 |
2018-01-05 |
王荣福 |
前列腺特异性肿瘤抗原及其用途
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
CN107708706A
(zh)
*
|
2015-05-29 |
2018-02-16 |
戴纳瓦克斯技术公司 |
用于治疗肺的癌症的多核苷酸Toll样受体9激动剂的肺内施用
|
|
US10751412B2
(en)
*
|
2015-05-29 |
2020-08-25 |
Merck Sharp & Dohme Corp. |
Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
|